ATE533488T1 - Verfahren und formulierungen zur modulierung von lyn-kinaseaktivität und behandlung assoziierter erkrankungen - Google Patents
Verfahren und formulierungen zur modulierung von lyn-kinaseaktivität und behandlung assoziierter erkrankungenInfo
- Publication number
- ATE533488T1 ATE533488T1 AT06813647T AT06813647T ATE533488T1 AT E533488 T1 ATE533488 T1 AT E533488T1 AT 06813647 T AT06813647 T AT 06813647T AT 06813647 T AT06813647 T AT 06813647T AT E533488 T1 ATE533488 T1 AT E533488T1
- Authority
- AT
- Austria
- Prior art keywords
- formulations
- kinase activity
- disorder
- compounds
- methods
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010033645 Pancreatitis Diseases 0.000 abstract 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 abstract 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 206010040047 Sepsis Diseases 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 208000018914 glucose metabolism disease Diseases 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 208000013223 septicemia Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70979805P | 2005-08-22 | 2005-08-22 | |
| US80853306P | 2006-05-26 | 2006-05-26 | |
| PCT/US2006/032788 WO2007024863A2 (en) | 2005-08-22 | 2006-08-22 | Methods and formulations for modulating lyn kinase activity and treating related disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE533488T1 true ATE533488T1 (de) | 2011-12-15 |
Family
ID=37635750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06813647T ATE533488T1 (de) | 2005-08-22 | 2006-08-22 | Verfahren und formulierungen zur modulierung von lyn-kinaseaktivität und behandlung assoziierter erkrankungen |
Country Status (11)
| Country | Link |
|---|---|
| US (8) | US7776870B2 (enExample) |
| EP (1) | EP1924262B1 (enExample) |
| JP (1) | JP5113752B2 (enExample) |
| KR (2) | KR101452518B1 (enExample) |
| AT (1) | ATE533488T1 (enExample) |
| AU (1) | AU2006283211B2 (enExample) |
| BR (1) | BRPI0615046C1 (enExample) |
| CA (1) | CA2620065C (enExample) |
| IL (1) | IL189603A0 (enExample) |
| NZ (1) | NZ565955A (enExample) |
| WO (1) | WO2007024863A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101452518B1 (ko) | 2005-08-22 | 2014-10-21 | 멜리어 파마슈티칼스 아이, 인코포레이티드 | Ｌｙｎ 키나제 활성의 조절 및 관련된 장애의 치료를 위한방법 및 제제 |
| WO2008103692A2 (en) * | 2007-02-20 | 2008-08-28 | Melior Pharmaceuticals I, Inc. | Methods of identifying activators of lyn kinase |
| WO2008147687A1 (en) * | 2007-05-21 | 2008-12-04 | Mayo Foundation For Medical Education And Research | Treating pancreatitis |
| US20100197710A1 (en) * | 2007-07-23 | 2010-08-05 | Melior Pharmaceuticals I, Inc. | Methods Of Activating IRS-1 And AKT |
| US8552184B2 (en) * | 2008-07-03 | 2013-10-08 | Melior Pharmaceuticals I, Inc. | Compounds and methods for treating disorders related to glucose metabolism |
| WO2011150300A1 (en) * | 2010-05-28 | 2011-12-01 | Melior Pharmaceuticals I, Inc. | Prevention of pancreatic beta cell degeneration |
| RU2646475C2 (ru) * | 2011-12-12 | 2018-03-05 | МЕЛИОР ФАРМАСЬЮТИКАЛЗ Ай, ИНК. | Лечение диабета I и II типа |
| US9687486B2 (en) * | 2012-12-20 | 2017-06-27 | The Trustees Of Columbia University In The City Of New York | Methods of treating atherosclerosis or myeloproliferative neoplasms by administering a lyn kinase activator |
| JOP20200093A1 (ar) | 2015-01-09 | 2017-06-16 | Kyowa Kirin Co Ltd | طريقة لإنتاج مشتق ثيازول |
| AU2018250795B2 (en) * | 2017-04-10 | 2022-02-10 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Treatment of adipocytes |
| AU2019223911A1 (en) | 2018-02-21 | 2020-07-23 | Melior Pharmaceuticals I, Inc. | Treatment of liver diseases |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3174901A (en) * | 1963-01-31 | 1965-03-23 | Jan Marcel Didier Aron Samuel | Process for the oral treatment of diabetes |
| US3922345A (en) | 1971-10-29 | 1975-11-25 | Pfizer | Pyrimidinones and hydroxy pyrimidines |
| BE790125A (fr) * | 1971-10-29 | 1973-04-16 | Pfizer | Nouvelles pyrimidinones et nouvelles hydroxypyrimidines |
| US4080454A (en) | 1976-07-16 | 1978-03-21 | Pfizer Inc. | 5-M-Tolyloxyuracil, anti-ulcer agent |
| US4612376A (en) | 1983-03-25 | 1986-09-16 | Fujisawa Pharmaceutical Co., Ltd. | Substituted-3,4-dihydro-4-(2,4,6-trimethoxyphenylimino)-2(1H)-pyrimidones useful as cardiotonic, antihypertensive, cerebrovascular vasodilator and anti-platelet agent |
| US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| GB9214720D0 (en) | 1992-07-10 | 1992-08-19 | Wellcome Found | Enzyme inhibitors |
| SE9203753D0 (sv) | 1992-12-11 | 1992-12-11 | Kabi Pharmacia Ab | Expression system for producing apolipoprotein ai-m |
| US5476855A (en) | 1993-11-02 | 1995-12-19 | Mahmoud H. el Kouni | Enzyme inhibitors, their synthesis and methods for use |
| US6900304B2 (en) | 1996-01-31 | 2005-05-31 | The Regents Of The University Of California | Emission ratiometric indicators of phosphorylation |
| US20020019346A1 (en) | 1997-05-21 | 2002-02-14 | Children's Medical Center Corporation | Treatment of prostate cancer by inhibiting lyn tyrosine kinase |
| US6037323A (en) | 1997-09-29 | 2000-03-14 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6004925A (en) | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6410255B1 (en) | 1999-05-05 | 2002-06-25 | Aurora Biosciences Corporation | Optical probes and assays |
| US20010036479A1 (en) | 2000-01-14 | 2001-11-01 | Gillian Cave | Glyburide composition |
| GB0104422D0 (en) | 2001-02-22 | 2001-04-11 | Glaxo Group Ltd | Quinoline derivative |
| US20030198666A1 (en) | 2002-01-07 | 2003-10-23 | Richat Abbas | Oral insulin therapy |
| US7985422B2 (en) | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
| US7232828B2 (en) | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
| US20050009817A1 (en) | 2003-04-30 | 2005-01-13 | Jennifer Savoy | Substituted heteroaryls |
| US20050208054A1 (en) | 2003-12-09 | 2005-09-22 | University Of Massachusetts | Methods of identifying insulin response modulators and uses therefor |
| EP1541694A1 (en) | 2003-12-12 | 2005-06-15 | Sirenade Pharmaceuticals AG | Methods of identifying, selecting and/or characterizing compounds which modulate the activity of a Src family kinase |
| US20060035302A1 (en) | 2004-06-21 | 2006-02-16 | Applera Corporation | Kinase substrates with multiple phosphorylation sites |
| ES2450566T3 (es) | 2004-11-30 | 2014-03-25 | Amgen Inc. | Análogos de quinazolina y quinolinas y su uso como medicamentos para tratar el cáncer |
| WO2007016975A1 (en) | 2005-07-29 | 2007-02-15 | F. Hoffmann-La Roche Ag | Kinase and phosphatase assays based on fret |
| US20070025953A1 (en) | 2005-07-27 | 2007-02-01 | Jones Michael R | Co-therapy for diabetic conditions |
| KR101452518B1 (ko) * | 2005-08-22 | 2014-10-21 | 멜리어 파마슈티칼스 아이, 인코포레이티드 | Ｌｙｎ 키나제 활성의 조절 및 관련된 장애의 치료를 위한방법 및 제제 |
| KR101012926B1 (ko) | 2005-09-01 | 2011-02-09 | 에프. 호프만-라 로슈 아게 | Ｐ2ｘ3 및 ｐ2ｘ2/3 조정자로서의 다이아미노피리미딘 |
| KR100881728B1 (ko) | 2007-05-04 | 2009-02-06 | 주식회사 하이닉스반도체 | 루테늄전극을 구비한 반도체소자 및 그 제조 방법 |
| US20100197710A1 (en) | 2007-07-23 | 2010-08-05 | Melior Pharmaceuticals I, Inc. | Methods Of Activating IRS-1 And AKT |
| US8552184B2 (en) | 2008-07-03 | 2013-10-08 | Melior Pharmaceuticals I, Inc. | Compounds and methods for treating disorders related to glucose metabolism |
| WO2010078300A1 (en) | 2008-12-29 | 2010-07-08 | The Board Of Trustees Of The University Of Alabama | Dual functioning ionic liquids and salts thereof |
| WO2011150300A1 (en) | 2010-05-28 | 2011-12-01 | Melior Pharmaceuticals I, Inc. | Prevention of pancreatic beta cell degeneration |
| JP2017507670A (ja) | 2014-02-24 | 2017-03-23 | エナジーシス ファーマシューティカルズ， インコーポレイテッド | ヒト褐色脂肪細胞前駆体の分化を誘導するための方法および組成物 |
| AU2018250795B2 (en) * | 2017-04-10 | 2022-02-10 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Treatment of adipocytes |
-
2006
- 2006-08-22 KR KR1020087006891A patent/KR101452518B1/ko active Active
- 2006-08-22 AT AT06813647T patent/ATE533488T1/de active
- 2006-08-22 CA CA2620065A patent/CA2620065C/en active Active
- 2006-08-22 US US11/507,652 patent/US7776870B2/en active Active
- 2006-08-22 KR KR1020147016962A patent/KR101577554B1/ko active Active
- 2006-08-22 EP EP06813647A patent/EP1924262B1/en active Active
- 2006-08-22 JP JP2008528076A patent/JP5113752B2/ja active Active
- 2006-08-22 AU AU2006283211A patent/AU2006283211B2/en active Active
- 2006-08-22 WO PCT/US2006/032788 patent/WO2007024863A2/en not_active Ceased
- 2006-08-22 BR BRPI0615046A patent/BRPI0615046C1/pt active IP Right Grant
- 2006-08-22 NZ NZ565955A patent/NZ565955A/en unknown
-
2008
- 2008-02-19 IL IL189603A patent/IL189603A0/en active IP Right Grant
-
2010
- 2010-07-15 US US12/837,067 patent/US8343985B2/en active Active
-
2012
- 2012-11-30 US US13/690,548 patent/US8835448B2/en active Active
-
2014
- 2014-02-18 US US14/182,380 patent/US9216959B2/en active Active
-
2015
- 2015-11-13 US US14/941,473 patent/US9763945B2/en active Active
-
2017
- 2017-08-23 US US15/684,130 patent/US10251883B2/en active Active
-
2019
- 2019-02-27 US US16/286,976 patent/US11033548B2/en active Active
-
2021
- 2021-05-07 US US17/314,543 patent/US12070461B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL189603A0 (en) | Methods and formulations for modulating lyn kinase activity and treating related disorders | |
| CY1120922T1 (el) | Παραγωγα πυρρολιου ως φαρμακευτικοι παραγοντες | |
| EA200870019A1 (ru) | Лактамовые соединения и способы их применения | |
| IL184898A0 (en) | Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same | |
| NO20074999L (no) | Metode og preparat for behandling av perifere vaskulaere sykdommer | |
| TW200745124A (en) | Azepinoindole derivatives as pharmaceutical agents | |
| EP1848432A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF PATHOLOGIES COMPRISING OBESITY, DIABETES, METABOLIC SYNDROMES, NEURODEGENERATIVE DISEASES, AND DISEASES ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION | |
| NO20084256L (no) | DPP IV inhibitorformuleringer | |
| EA200801842A1 (ru) | Антитела против бета-амилоидного пептида | |
| DE602004014117D1 (de) | Thiazole zur verwendung als inhibitoren von protein-kinasen | |
| GEP20125565B (en) | Lactam compounds and their pharmaceutical use | |
| WO2007122580A3 (en) | Compositions of phenylephrine useful for treatment of respiratory illness | |
| WO2007062078A3 (en) | Thrombopoietin activity modulating compounds and methods | |
| MX2009006345A (es) | Compuestos utiles como inhibidores de proteina cinasa. | |
| MX2007004765A (es) | Compuestos y metodos que modulan la actividad de la trombopoyetina. | |
| WO2006138608A3 (en) | Pharmaceutical compositions and use thereof | |
| NO20076405L (no) | Anvendelse av 24-nor-UDCA | |
| ATE542814T1 (de) | Pyrazinkinaseinhibitoren | |
| DE602004017326D1 (de) | Tetrahydrocarbazolderivate und deren pharmazeutische verwendung | |
| WO2006020680A3 (en) | Heterocyclic compounds as pharmaceutical agents | |
| TNSN08385A1 (en) | Delayed-release glucocorticoid treatment of rheumatoid disease | |
| DK1711185T3 (da) | Kombination af roscovitin-CS-682 eller dens metabolit CNDAC | |
| IL179206A0 (en) | Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same | |
| UA94213C2 (ru) | Применение полипептида одноцепочечного антитела, который подавляет активность cd40 или cd40l в приготовлении медикамента для лечения аутоиммунного заболевания | |
| EA200501301A1 (ru) | Ментоловые растворы лекарственных препаратов |